Management of Osteoporosis

Publication Date: September 24, 2019

Key Points

Key Points

Patients with non-metastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to the added risks associated with their cancer therapy.

Clinicians are advised to assess fracture risk using established tools.
  • For those with substantial risk of osteoporotic fracture the clinician should obtain a bone mineral density.

The bone health of all patients may benefit from optimizing nutrition, exercise and lifestyle.

When a pharmacologic agent is indicated, bisphosphonates or denosumab, at osteoporosis-indicated dosages, are the preferred interventions.

Assessment

...essment...

Risk

...ndation 1.1. It is recommended that pa...

...commendation 1.2. Clinicians should be...

...endation 1.3. Clinicians may use a ri...


...reening...

...ecommendation 2.1. Patients with non-meta...

...ommendation 2.2. Patients with non-metastatic c...


Treatment

...atment...

...n-pharmacological Interventi...

...tion 3.1. Clinicians should encourage patients to...

...ommendation 3.2. Clinicians should actively encour...

...tion 3.3. Clinicians should actively encourage pat...


...acological Intervention

...ommendation 3.4. For patients with non-metastatic...

...ndation 3.5. Provided T-score and/or...


...ure 1. Algorithm for Maintaining Bone Hea...


...oporotic Fracture Risk FactorsHaving tro...


...able 2. Bone Loss Associated with V...


...y used Bone Modifying Agents for the Prevention...


...Estimated Drug Costs for Bone Modifying...